Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KRRO Korro Bio	$12.35 -0.9%	$14.60	$10.29 ▼ $98.00	$115.97M	2.45	110,006 shs	131,615 shs
LVTX LAVA Therapeutics	$1.31 -2.2%	$1.29	$0.85 ▼ $2.39	$34.47M	0.48	155,871 shs	15,523 shs
LXEO Lexeo Therapeutics	$3.91 -7.8%	$3.36	$1.45 ▼ $19.50	$129.80M	0.52	528,171 shs	756,031 shs
NKTX Nkarta	$1.77 -2.7%	$1.88	$1.31 ▼ $8.23	$125.60M	0.72	1.05 million shs	416,431 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KRRO Korro Bio	0.00%	-8.79%	-10.51%	-48.61%	-65.09%
LVTX LAVA Therapeutics	0.00%	0.00%	+2.34%	+0.77%	-29.57%
LXEO Lexeo Therapeutics	0.00%	-0.76%	+38.65%	-4.40%	-75.86%
NKTX Nkarta	0.00%	-4.84%	+1.14%	+14.19%	-67.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KRRO Korro Bio	1.9118 of 5 stars	3.6	3.0	1.1	0.0	0.6
LVTX LAVA Therapeutics	1.7011 of 5 stars	3.0	5.0	0.0	0.0	0.0
LXEO Lexeo Therapeutics	1.9019 of 5 stars	3.5	2.0	0.0	2.5	0.6
NKTX Nkarta	3.1856 of 5 stars	4.6	3.0	1.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KRRO Korro Bio	3.29	Buy	$102.43	729.38% Upside
LVTX LAVA Therapeutics	2.00	Hold	$3.17	141.73% Upside
LXEO Lexeo Therapeutics	3.00	Buy	$16.60	324.55% Upside
NKTX Nkarta	3.13	Buy	$14.33	709.79% Upside

Current Analyst Ratings Breakdown

Latest LVTX, NKTX, LXEO, and KRRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
5/30/2025	LXEO Lexeo Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $10.00
5/16/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $15.00
5/15/2025	LVTX LAVA Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/15/2025	NKTX Nkarta	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
5/15/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
5/13/2025	KRRO Korro Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
5/13/2025	KRRO Korro Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$155.00 ➝ $90.00
5/13/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $20.00
5/8/2025	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$115.00 ➝ $100.00
4/29/2025	KRRO Korro Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KRRO Korro Bio	$2.27M	51.09	N/A	N/A	$17.12 per share	0.72
LVTX LAVA Therapeutics	$11.98M	2.88	N/A	N/A	$1.06 per share	1.24
LXEO Lexeo Therapeutics	$650K	199.69	N/A	N/A	$3.53 per share	1.11
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.78 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KRRO Korro Bio	-$83.58M	-$9.44	N/A	N/A	N/A	N/A	-51.64%	-37.94%	8/12/2025 (Estimated)
LVTX LAVA Therapeutics	-$25.11M	-$1.04	N/A	N/A	N/A	N/A	-86.38%	-34.12%	8/19/2025 (Estimated)
LXEO Lexeo Therapeutics	-$98.33M	-$3.30	N/A	N/A	N/A	N/A	-85.86%	-68.48%	8/11/2025 (Estimated)
NKTX Nkarta	-$108.79M	-$1.51	N/A	N/A	N/A	N/A	-26.64%	-21.62%	8/12/2025 (Estimated)

Latest LVTX, NKTX, LXEO, and KRRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	LVTX LAVA Therapeutics	-$0.37	-$0.13	+$0.24	-$0.13	N/A	N/A
5/14/2025	Q1 2025	NKTX Nkarta	-$0.44	-$0.43	+$0.01	-$0.43	N/A	N/A
5/12/2025	Q1 2025	LXEO Lexeo Therapeutics	-$0.80	-$0.99	-$0.19	-$0.99	N/A	N/A
5/7/2025	Q1 2025	KRRO Korro Bio	-$2.60	-$2.49	+$0.11	-$2.49	$0.13 million	$2.55 million
3/28/2025	Q4 2024	LVTX LAVA Therapeutics	-$0.32	-$0.14	+$0.18	-$0.14	$2.40 million	$2.50 million
3/26/2025	Q4 2024	NKTX Nkarta	-$0.41	-$0.35	+$0.06	-$0.35	N/A	N/A
3/24/2025	Q4 2024	LXEO Lexeo Therapeutics	-$0.87	-$0.78	+$0.09	-$0.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
LVTX LAVA Therapeutics	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KRRO Korro Bio	N/A	9.41	9.41
LVTX LAVA Therapeutics	N/A	6.73	6.73
LXEO Lexeo Therapeutics	0.01	3.42	3.42
NKTX Nkarta	N/A	14.48	14.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KRRO Korro Bio	13.18%
LVTX LAVA Therapeutics	N/A
LXEO Lexeo Therapeutics	60.67%
NKTX Nkarta	80.54%

Insider Ownership

Company	Insider Ownership
KRRO Korro Bio	4.60%
LVTX LAVA Therapeutics	9.50%
LXEO Lexeo Therapeutics	5.30%
NKTX Nkarta	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KRRO Korro Bio	70	9.39 million	8.96 million	No Data
LVTX LAVA Therapeutics	60	26.31 million	23.81 million	Optionable
LXEO Lexeo Therapeutics	58	33.20 million	31.44 million	Not Optionable
NKTX Nkarta	140	70.96 million	65.00 million	Optionable

LVTX, NKTX, LXEO, and KRRO Headlines

Recent News About These Companies

Nkarta (NASDAQ:NKTX) Given New $14.00 Price Target at Mizuho

June 10, 2025 | marketbeat.com

Nkarta, Inc. (NASDAQ:NKTX) Receives Consensus Recommendation of "Buy" from Analysts

June 10, 2025 | marketbeat.com

Bank of America Corp DE Grows Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX)

June 8, 2025 | marketbeat.com

Nkarta CMO David Shook Steps Down, Shawn Rose To Succeed

June 8, 2025 | nasdaq.com

Nkarta, Inc.: Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

June 6, 2025 | finanznachrichten.de

Nkarta, Inc. Appoints Dr. Shawn Rose as Chief Medical Officer and Head of R&D

June 6, 2025 | quiverquant.com

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

June 6, 2025 | globenewswire.com

Millennium Management LLC Boosts Position in Nkarta, Inc. (NASDAQ:NKTX)

June 4, 2025 | marketbeat.com

Jefferies Financial Group Inc. Boosts Stock Position in Nkarta, Inc. (NASDAQ:NKTX)

May 28, 2025 | marketbeat.com

BNP Paribas Financial Markets Invests $507,000 in Nkarta, Inc. (NASDAQ:NKTX)

May 26, 2025 | marketbeat.com

AWM Investment Company Inc. Makes New $996,000 Investment in Nkarta, Inc. (NASDAQ:NKTX)

May 23, 2025 | marketbeat.com

Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade

May 19, 2025 | zacks.com

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

May 15, 2025 | benzinga.com

William Blair Downgrades Nkarta (NKTX)

May 15, 2025 | msn.com

Nkarta, Inc.: Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

May 15, 2025 | finanznachrichten.de

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

May 14, 2025 | globenewswire.com

Nkarta (NKTX) Upgraded to Buy: Here's Why

April 14, 2025 | zacks.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), Nkarta (NKTX) and Regeneron (REGN)

April 9, 2025 | markets.businessinsider.com

Nkarta to Participate in an April Investor Conference

April 1, 2025 | globenewswire.com

Nkarta: Betting On The Turnaround

March 31, 2025 | seekingalpha.com

Nkarta: Betting On The Turnaround

March 31, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LVTX, NKTX, LXEO, and KRRO Company Descriptions

Korro Bio NASDAQ:KRRO

$12.35 -0.11 (-0.88%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$12.37 +0.02 (+0.16%)

As of 07:20 AM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

LAVA Therapeutics NASDAQ:LVTX

$1.31 -0.03 (-2.24%)

Closing price 06/20/2025 03:56 PM Eastern

Extended Trading

$1.34 +0.03 (+2.29%)

As of 07:28 AM Eastern

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Lexeo Therapeutics NASDAQ:LXEO

$3.91 -0.33 (-7.78%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$3.89 -0.02 (-0.51%)

As of 07:08 AM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Nkarta NASDAQ:NKTX

$1.77 -0.05 (-2.75%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.78 +0.00 (+0.28%)

As of 07:11 AM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time